经动脉化疗栓塞序贯125I植入治疗中晚期肝癌疗效观察

doi:10.3969/j.issn.1009-976X.2014.01.010

岭南现代临床外科 ›› 2014, Vol. 14 ›› Issue (01): 33-36.DOI: 10.3969/j.issn.1009-976X.2014.01.010

经动脉化疗栓塞序贯¹²⁵I植入治疗中晚期肝癌疗效观察

欧章松¹,张启周¹,胡倩²,丁林潇潇²,姚和瑞²

1. 广东省中西医结合医院
2. 中山大学孙逸仙纪念医院

通讯作者: 张启周
基金资助:
国家自然科学基金;教育部博士点基金;中山大学青年教师重点培育项目

Curative effect of transcatheter arterial chemoembolization combined with ¹²⁵I implantation in the treatment of Middle-advanced hepatic carcinoma

Ou Zhangsong, Zhang Qizhou, Hu Qian, Ding-Lin Xiaoxiao, Yao Herui

1.Guangdong Province Hospital of combination of traditional Chinese and Western Medicine 2.Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Received:2013-11-18 Revised:2013-11-27 Online:2014-02-20 Published:2014-02-20
Contact: Zhang Qizhou

摘要/Abstract

摘要：

【摘要】目的探讨经动脉化疗栓塞术(TACE)序贯125I放射性粒子植入治疗中晚期肝癌的临床疗效。方法回顾性研究自2011年5月至2012年5月确诊为中晚期原发性肝癌的患者89例,A组45例(单纯TACE术),B组44例(TACE术后7~10天内序贯125I放射性粒子植入),125I放射性粒子植入严格遵从计算机三维治疗计划系统(TPS)的方案进行粒子布源。对比观察两组患者术后2、4个月的CT扫描显示的肿瘤局部控制有效率及术后6、9个月的生存率,两组局部控制率及术后6、9个月生存率比较采用卡方检验。结果随访术后第2、4月肿瘤局部控制有效率(CR+PR)A组是24.44%(11/45),17.78%(8/45),B组为54.55%(24/44),47.73%(21/44),P<0.05,两组差异比较具有统计学意义。A组术后6、9个月存活率分别是62.22%(28/45),42.22%(19/45),B组术后6、9个月存活率分别是90.91%(40/44),72.73%(32/44),两组同期P值均小于0.05,两组差异具有统计学意义。结论经肝动脉化疗栓塞序贯125I放射性粒子植入治疗中晚期原发性肝癌临床疗效确切,提高生存率。

关键词: 肝细胞癌;经动脉化疗栓塞术;¹²⁵I放射性粒子

Abstract:

【Abstract】 Objective To discuss the therapeutic effect of transcatheter hepatic arterial chemoemb-olization(TACE) combined with 125I radioactive particles implantation for the treatment of middle-advanced hepatic carcinoma. Methods Eighty-nine cases of hepatic carcinoma were collected from May 2011 to May 2012 and retrospectively analyzed. Of 89 cases, 45 patients were underwent TACE alone (group A), 44 were treated with TACE combined with 125I radioactive particles implantation (group B) under the computer-assisted three-dimensional treatment planning system (TPS). Efficacy evaluation was performed in two months, four months after operation by CT scan. The survival status was recorded in the fourth and ninth months after treatment. Efficacy evaluation and survival status were compared between two groups by chi-square test (P<0.05). Results The OR (CR+PR) were 24.44% (11/45), 17.78% (8/45) in group A, and 54.55% (24/44), 47.73% (21/44) in group B respectively at two months and four months after operation. There were significant differences between two groups (P<0.05). The survival rate at six, nine months in group A (62.22%, 42.22%) were significantly lower than those in group B (90.91%,72.73%),P<0.05. Conclusion TACE combined with 125I radioactive particles implantation is an effective method for the treatment of middle-advanced hepatic carcinoma, which would also improved survival rate.

Key words: Hepatocellular carcinoma, TACE, ¹²⁵I radioactive particles

中图分类号:

R657.3

欧章松张启周胡倩丁林潇潇姚和瑞. 经动脉化疗栓塞序贯¹²⁵I植入治疗中晚期肝癌疗效观察[J]. 岭南现代临床外科, 2014, 14(01): 33-36.

Ou Zhangsong, Zhang Qizhou, Hu Qian, Ding-Lin Xiaoxiao, Yao Herui. Curative effect of transcatheter arterial chemoembolization combined with ¹²⁵I implantation in the treatment of Middle-advanced hepatic carcinoma[J]. Lingnan Modern Clinics in Surgery, 2014, 14(01): 33-36.

参考文献

[l] 陈万青,邹小农,张思维.中国肝癌死亡率地理分布分析[J].实用肿瘤学杂志,2008,22(3):201-203.
[2] 叶家才,崔书中,巴明臣.原发性肝癌的流行病学特征及其危险因素[J].实用医学杂志,2008,24(10):1839.
[3] 钦伦秀,孙惠川,汤钊散.原发性肝癌研究进展[J].中华外科杂志,2006,44:1070.
[4] Hübner M, McCormack L, Clavien PA. Surgical therapy of liver tumors: resection vs. ablation [J]. Praxis, 2005, 94:1255-1259.
[5] Lencioni R，de Baere T，Burrel M，et al．Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead(DEBDOX):technical recommendations[J]． Cardiovasc Intervent Radiol，2012，35( 5) :980-985．
[6] LivraghiT,Goldberg SN,Lazzaroni S, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions[J].Radiology, 2000,214:761-768.
[7] Llovet JM,Di Bisceglie AM，Bruix J，et al. Design and endpoints of clinical trials in hepatocellular carcinoma[J]．J Natl Cancer Inst.2008.100:698-711．
[8] Kume A，Nimura Y，Kamiya J，et al． Percutaneous ethanol injection via an artificially induced right hydrothorax for hepatocellular carcinoma in the hepatic dome[J]． Cardiovasc Intervent Radiol，2003，26( 6) : 543-549．
[9] 李力军，于世平，孙兴臣，等．放射性粒子组织间永久植入治疗晚期胰腺癌［J］．中华外科杂志，2003，41( 9) : 717．
[10] 黄文才,沈钧康,钱铭辉,等.肝脏急性放射性损伤超顺磁性氧化铁增强 MRI 实验研究[J]. 中华放射学杂志, 2007, 41(01): 95-97.
[11] Popescu CC，Wise J，Sowards K，et a1．Dosimetric characteristics of the Pharma Seed model BT-125-I source[J]. Med Phys, 2000, 27(5):2174-2181.
[12] 贺克武，高斌．ＣＴ导引下125Ｉ粒子组织间植入治疗肿瘤的新进展［Ｊ］．临床放射学杂志，2007,26:926-928.
[13] 付吕平, 郭志远, 刘卫红，等. TACE 联合放射性125I 粒子瘤内植入治疗肝癌 [J]. 标记免疫分析与临床,2013,20:207-209

[1]	王卫东. 双极射频Habib 4X在完全腹腔镜肝切除术中的应用[J]. 岭南现代临床外科, 2014, 14(01): 5-7.
[2]	黎艳欢魏娟. 经皮肝动脉插管化疗栓塞术治疗肝癌患者的同步营养干预[J]. 岭南现代临床外科, 2013, 13(03): 270-.

经动脉化疗栓塞序贯¹²⁵I植入治疗中晚期肝癌疗效观察

Curative effect of transcatheter arterial chemoembolization combined with ¹²⁵I implantation in the treatment of Middle-advanced hepatic carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics